Study S003406

A Phase 1/2a, Randomized, Double Blind, Placebo Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SRSD384 in Overweight or Obese Participants

ClinicalTrials.gov record

Registration

Registration: NCT07557355
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1; PHASE2
Masking: QUADRUPLE
Status: NOT_YET_RECRUITING
Enrollment: 78
Start: 2026-06
Primary completion: 2027-10
Lead sponsor: Sirius Therapeutics Co., Ltd.
Conditions: Overweight , Obesity
Interventions: DRUG:SRSD384 injection; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Incidence of treatment-emergent adverse events (TEAEs) [168 days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.